Lenvima (lenvatinib) is a cancer medication approved to treat four types of cancer: differentiated thyroid cancer, kidney cancer, liver cancer, and endometrial cancer. It works by blocking signals that tumors need to grow blood vessels and sustain themselves. Depending on the cancer type, Lenvima is used either on its own or in combination with another drug.
How Lenvima Works
Cancer cells rely on building new blood vessels to feed their growth, a process called angiogenesis. Lenvima blocks multiple receptor proteins on the surface of cells that drive this process, cutting off the tumor’s blood supply and slowing or stopping its growth. It also interferes with other signaling pathways that some cancers exploit, including a protein called RET that plays a role in certain thyroid cancers. This multi-target approach is what makes the drug useful across several different cancer types.
Lenvima is taken as a daily oral capsule, which distinguishes it from many cancer treatments that require IV infusion.
Differentiated Thyroid Cancer
Lenvima’s first approval was for differentiated thyroid cancer, the most common form of thyroid cancer. It’s specifically used when the cancer has spread or come back locally, has progressed despite treatment, and no longer responds to radioactive iodine therapy. Radioactive iodine is the standard first-line treatment for this cancer, but some tumors eventually stop absorbing it, leaving patients with fewer options.
In this setting, Lenvima has shown strong results. The National Comprehensive Cancer Network lists it as the preferred agent for progressive radioactive iodine-refractory thyroid cancer, with a response rate of 65%, compared to 12% for sorafenib, the other approved option. In a real-world study of patients on Lenvima, median progression-free survival reached 35.2 months and median overall survival was 56.2 months. The standard starting dose is 24 mg taken once daily, though oncologists sometimes adjust it based on tolerability.
There is also emerging data supporting the combination of Lenvima with pembrolizumab (Keytruda) for anaplastic thyroid cancer, a rarer and more aggressive subtype, though this use is not yet a standard approval.
Advanced Kidney Cancer
Lenvima is approved in two different combinations for advanced kidney cancer (renal cell carcinoma), depending on where the patient is in their treatment journey.
For first-line treatment, Lenvima is paired with pembrolizumab (Keytruda), an immunotherapy drug. This combination produced some of the strongest outcomes seen in kidney cancer trials. Patients on the combination had a median progression-free survival of 23.9 months, compared to 9.2 months for patients on sunitinib, the previous standard of care. The overall response rate was 71%, with 16% of patients achieving a complete response, meaning no detectable cancer remained on imaging. Those numbers were roughly double the response rates seen with sunitinib alone.
For patients whose cancer has progressed after a prior treatment targeting blood vessel growth, Lenvima is approved in combination with everolimus as a second-line option.
Unresectable Liver Cancer
Lenvima is approved as a first-line treatment for hepatocellular carcinoma, the most common type of primary liver cancer, when surgery isn’t an option. Its approval was based on a large trial of 954 patients comparing it head-to-head with sorafenib, which had been the only first-line systemic option for over a decade.
Lenvima demonstrated non-inferior overall survival, with patients living a median of 13.6 months compared to 12.3 months on sorafenib. While those numbers may sound close, Lenvima showed advantages in other measures like response rate and progression-free survival, giving oncologists an alternative first-line choice for patients with advanced liver cancer.
Advanced Endometrial Cancer
Lenvima is used in combination with pembrolizumab for advanced endometrial cancer (uterine cancer) under specific circumstances. This combination is reserved for patients whose tumors are not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). These biomarker terms describe a subset of endometrial cancers that tend to respond well to immunotherapy alone. For the remaining patients whose tumors lack those features, immunotherapy by itself is less effective, and the Lenvima-pembrolizumab combination fills that gap.
To qualify, patients must have already tried at least one prior systemic therapy and must not be candidates for curative surgery or radiation. This makes it a later-line option for a population that previously had limited choices.
Common Side Effects
Lenvima’s side effect profile reflects its broad mechanism of action. Because it blocks blood vessel signaling throughout the body, certain effects are predictable and common. In studies of the Lenvima-pembrolizumab combination, the most frequently reported side effects were fatigue (63%), diarrhea (62%), musculoskeletal pain (58%), underactive thyroid (57%), and high blood pressure (56%).
High blood pressure is one of the most clinically significant side effects and typically requires monitoring and management with blood pressure medication throughout treatment. Underactive thyroid (hypothyroidism) is also very common and usually managed with thyroid hormone replacement. Many patients need dose reductions at some point during treatment to keep side effects manageable, and oncology teams expect this. A dose reduction doesn’t necessarily mean the drug stops working. Real-world data from thyroid cancer patients on reduced doses still showed meaningful progression-free survival.
Other notable side effects include decreased appetite, nausea, protein in the urine, and mouth sores. The severity varies considerably from person to person, and your treatment team will adjust the dose or temporarily pause treatment if needed.